Firefly Neuroscience
Firefly Neuroscience is an AI-powered neurodiagnostic company whose FDA-cleared Evoke System and BNA platform use qEEG/ERP analysis against a 191,000-record proprietary database to assess brain function for clinicians, defense health, and pharmaceutical customers.
- Company typePublic
- Founded2024
- HeadquartersHerzliya, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Firefly Neuroscience does
Firefly Neuroscience is a neurotechnology company that has built an FDA 510(k)-cleared platform for objective measurement of brain function, targeting healthcare providers, government/defense health buyers, and pharmaceutical companies. The company's core product is the Evoke System, a Class II neurodiagnostic device that combines quantitative EEG (qEEG), event-related potentials (ERP), and behavioral performance to capture both resting brain activity and cognitive response during structured tasks. Signals are processed through the company's proprietary BNA (Brain Network Analytics) AI engine, which compares each session against a normative database of over 191,000 EEG/ERP recordings — the largest known standardized repository in the field. Clinicians access results through the MyBNA cloud portal, supporting use cases in concussion, TBI, cognitive decline, depression, anxiety, ADHD, and PTSD.
The company monetizes through licensing and subscription arrangements for the Evoke/BNA platform sold to neurology, psychiatry, and TMS practices, supplemented by non-exclusive distribution of Zeto's FDA-cleared EEG headsets integrated with BNA. Firefly has secured enterprise validation through partnerships with the U.S. Department of War (PTSD/TBI assessment for active-duty service members and veterans), Neurology Consultants of Dallas (cognitive decline biomarkers), Nvidia (AI compute infrastructure for a foundation brain model), and pharma collaborators including Novartis and Takeda. Headquartered in Kenmore, NY with R&D origins in Israel, Firefly went public on NASDAQ (ticker: AIFF) via an approximately $45 million reverse merger with WaveDancer in August 2024 and subsequently acquired Evoke Neuroscience for $6 million in May 2025 to expand its EEG/ERP data assets and patent portfolio.
Firefly Neuroscience firmographics
Firmographics- Name
- Firefly Neuroscience
- Legal name
- Firefly Neuroscience Inc.
- Website
- https://fireflyneuro.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Firefly Neuroscience is an AI-powered neurodiagnostic company whose FDA-cleared Evoke System and BNA platform use qEEG/ERP analysis against a 191,000-record proprietary database to assess brain function for clinicians, defense health, and pharmaceutical customers.
- Ownership category
- akta.pro rank
Firefly Neuroscience industry classification
Industry- Product category
- Neurodiagnostic Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Neurodiagnostic Centers (EEG/EMG/NCS) (HLAFAKAK), Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Firefly Neuroscience is headquartered
LocationHeadquarters
- HQ city
- Herzliya
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Firefly Neuroscience business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- Evoke System Platform: Firefly generates revenue through licensing and subscription arrangements for its FDA-cleared Evoke system and BNA technology platform, sold to healthcare providers including neurology, psychiatry, and TMS practices for clinical brain assessment.
- EEG Hardware Distribution: Revenue from non-exclusive distribution of Zeto's FDA-cleared EEG headsets (WR19 and Zeto ONE), integrated with Firefly's BNA technology.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Firefly Neuroscience product offering
Product offeringCore offering
Firefly Neuroscience develops and sells the FDA 510(k)-cleared Evoke™ System, a Class II neurodiagnostic device that combines quantitative EEG (qEEG) and event-related potentials (ERP) to measure brain function in clinical settings. Its BNA™ (Brain Network Analytics) AI platform analyzes recorded EEG/ERP sessions against a proprietary normative database of over 191,000 recordings, producing interpretable reports accessed by clinicians through the MyBNA cloud portal. The company also distributes Zeto's FDA-cleared EEG headsets as a non-exclusive channel partner and licenses its BNA technology to clinical research and pharmaceutical collaborators.
Product overview
Firefly Neuroscience offers a unified neurodiagnostic platform centered on the FDA-cleared Evoke™ System. The Evoke System combines quantitative EEG (qEEG) and event-related potentials (ERP) in a single clinic-ready device, powered by the proprietary BNA™ (Brain Network Analytics) technology. The BNA technology analyzes brain signals against a normative database of over 191,000 EEG/ERP sessions to generate interpretable reports. Clinicians access results through the MyBNA cloud-based portal. The company also acquired Evoke Neuroscience in May 2025 to expand its database and patent portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- Evoke System: FDA-cleared neurodiagnostic device combining quantitative EEG (qEEG) and event-related potentials (ERP) for brain function assessment.
- BNA (Brain Network Analytics)
Products and services
- Evoke™ System FDA 510(k)-cleared Class II neurodiagnostic device that combines quantitative EEG (qEEG), event-related potentials (ERP), and behavioral performance to measure brain function. It captures both baseline brain activity at rest and cognitive response during structured tasks, translating complex brain signals into interpretable reports for clinicians assessing patients aged approximately 12-85. Built on a proprietary database of over 191,000 EEG/ERP sessions for comparison against age-matched normative cohorts. Used by neurologists, psychiatrists, TMS providers, and cognitive care specialists for conditions including concussion, TBI, cognitive decline, depression, anxiety, ADHD, and neurodegenerative disorders.
- BNA™ (Brain Network Analytics) AI-powered analysis technology that automatically analyzes EEG and ERP recordings against Firefly's proprietary normative database of over 191,000 sessions. Produces interpretable reports comparing patient brain activity against age-matched cohorts without requiring preprocessing or advanced interpretation skills. Supports clinical decision-making, biomarker discovery, and applications in CNS clinical trial endpoints and companion diagnostics for pharmaceutical collaborators.
- MyBNA Cloud-based clinician portal for accessing and reviewing BNA reports. Clinicians log in to view patient results, track brain function changes over time, and support treatment decisions for individual patients.
- Zeto EEG Headset Distribution (WR19 and Zeto ONE) Non-exclusive distribution of Zeto's FDA-cleared EEG headsets (WR19 and Zeto ONE) integrated with Firefly's BNA technology, used in 200+ hospitals and neurology offices across the US. Enables broader deployment of BNA-enabled assessments to facilities using Zeto's EEG platform.
Quantifiable outcome
- 1.5x improvement in remission rates based on analysis of over 2,200 patients using BNA
- +4 more outcomes
Companies that use Firefly Neuroscience
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Firefly Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
Firefly Neuroscience partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- U.S. Department of WarcorePublic-private partnership to deploy FDA-cleared AI-powered EEG/ERP technology for assessing and treating PTSD and TBI in active-duty U.S. service members and veterans. Addresses multi-billion dollar military mental health crisis affecting over 444,000 service members diagnosed with TBI between 2000-2021.
- Evoke NeurosciencecoreAcquisition of Evoke Neuroscience for $6 million to strengthen foundation model of the human brain, expand EEG/ERP data resources, enhance proprietary database and patent portfolio, supporting growth in brain health assessment technology.
- Nvidia Partner Connect ProgramcorePartnership providing access to Nvidia's AI software and hardware to advance Firefly's FDA-cleared Brain Network Analytics platform and support development of a comprehensive model of the human brain.
- ZetocoreNon-exclusive distribution partnership making Firefly a distributor for Zeto's FDA-cleared EEG headsets (WR19 and Zeto ONE). Collaboration includes integration of Firefly's BNA technology with EEG platforms used in 200+ hospitals and neurology offices across the US.
- Neurology Consultants of DallascoreStrategic partnership to enhance early detection efforts and disease management for patients with cognitive disorders. NCD incorporates Firefly's BNA technology into patient workflow and conducts clinical studies aimed at identifying biomarkers for predicting dementia onset to optimize patient care pathways.
Scale indicators9 records
Recent moves7 records
Expansion highlights7 records
Firefly Neuroscience competitors and assessment
Company assessmentDirect peers
- Ceribell: Ceribell offers FDA-cleared AI-powered EEG systems for hospital bedside brain monitoring. Directly comparable to Firefly's Evoke platform as an AI-driven neurodiagnostic with FDA clearance targeting clinical decision support.
- Compumedics Limited: Compumedics designs and manufactures EEG and sleep diagnostic systems used in hospitals and research institutions globally. Directly comparable to Firefly's Evoke EEG-based neurodiagnostic platform, with overlapping customer base of neurologists and sleep specialists.
- BrainScope: BrainScope develops EEG-based AI algorithms for traumatic brain injury assessment, including FDA-cleared products. Highly comparable to Firefly's Department of War TBI/PTSD positioning and EEG biomarker approach.
- Wave Neuroscience: Wave Neuroscience provides EEG-based brain mapping and neurofeedback technologies for clinical and research use. Directly comparable to Firefly's qEEG/ERP brain function assessment offering.
- Cadwell Industries: Cadwell manufactures neurodiagnostic equipment including EEG systems sold to hospitals and neurology practices. Comparable product category and customer base as Firefly's Evoke system.
- ANT Neuro: ANT Neuro provides EEG and MEG systems for clinical and research applications. Comparable as a neurodiagnostic EEG equipment vendor with overlapping neuroscience research customer base.
Broad incumbents
- Natus Medical: Natus is a leading provider of neurodiagnostic, hearing, and balance equipment with deep hospital sales channels. Overlaps with Firefly's EEG-based clinical assessment offering but operates as a broader neurodiagnostic portfolio incumbent.
- Neuronetics: Neuronetics is a commercial-stage neurotechnology company focused on transcranial magnetic stimulation (TMS) for depression. Comparable to Firefly's TMS provider customer segment, where BNA is used for treatment monitoring and evaluation.
Emerging players
- Persyst: Persyst develops EEG interpretation software used alongside EEG hardware in clinical settings. Partial overlap with Firefly's BNA AI analysis layer, though Persyst focuses on seizure detection rather than qEEG/ERP.
- iMediSync: iMediSync develops AI-driven EEG-based diagnostic solutions for early detection of neurological conditions including Alzheimer's. Emerging player with adjacent technology and biomarker-focused approach similar to Firefly's BNA platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Firefly Neuroscience social profiles
Digital presenceFirefly Neuroscience compliance and trust
Trust signalCompliance3 records
Firefly Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Firefly Neuroscience leadership team
Management profileNumber of profiles
Profiles6 records
Firefly Neuroscience subsidiaries and ownership
Company hierarchySubsidiaries1 record
Firefly Neuroscience funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Firefly Neuroscience M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Firefly Neuroscience
What does Firefly Neuroscience do?
Firefly Neuroscience develops and sells the FDA 510(k)-cleared Evoke™ System, a Class II neurodiagnostic device that combines quantitative EEG (qEEG) and event-related potentials (ERP) to measure brain function in clinical settings. Its BNA™ (Brain Network Analytics) AI platform analyzes recorded EEG/ERP sessions against a proprietary normative database of over 191,000 recordings, producing interpretable reports accessed by clinicians through the MyBNA cloud portal. The company also distributes Zeto's FDA-cleared EEG headsets as a non-exclusive channel partner and licenses its BNA technology to clinical research and pharmaceutical collaborators.
Is Firefly Neuroscience a public or private company?
Firefly Neuroscience is a public company. It is classified as public and is currently operating.
When was Firefly Neuroscience founded?
Firefly Neuroscience was founded in 2024. It employs 11 to 50 people.
Where is Firefly Neuroscience based?
Firefly Neuroscience is headquartered in Herzliya, Israel, in the Middle East region.
How does Firefly Neuroscience make money?
Two revenue lines are on record. Evoke System Platform is the primary driver. The others are EEG Hardware Distribution.
Who are Firefly Neuroscience's main competitors?
Direct peers on record are Ceribell, Compumedics Limited, BrainScope, Wave Neuroscience, Cadwell Industries and ANT Neuro. Broad incumbents are Natus Medical and Neuronetics. Emerging players are Persyst and iMediSync.
Does Firefly Neuroscience have an API?
No public API is recorded for Firefly Neuroscience.
What industry is Firefly Neuroscience in?
Firefly Neuroscience's product category is Neurodiagnostic Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLAFAKAK, Neurodiagnostic Centers (EEG/EMG/NCS). Its NAICS code is 334510 and its SIC code is 3845.